📰 Priority Review News
Page 64 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
April 17, 2023
FDA Advisory Committee to review sulbactam-durlobactam for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter ... | April 17, 2023
April 17, 2023
New Drug Application for sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of... | April 17, 2023
April 17, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based...
April 10, 2023
The antibody-drug conjugates market is anticipated to surge as several pharma companies across the globe are thoroughly working toward the development and expansion to treat a wide array of
April 10, 2023
/PRNewswire/ -- DelveInsights Antibody-drug Conjugates Market Insights report delivers an in-depth understanding of the ADCs and the antibody-drug conjugates...
April 5, 2023
/PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that...
April 5, 2023
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and...
April 4, 2023
/PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that its partner Eisai has published an article about long-term health outcomes...
April 4, 2023
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of...
April 4, 2023
STOCKHOLM, April 4, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that...